The Food and Drug Administration (FDA) has approved Rocklatan (netarsudil 0.02% and latanoprost 0.005% ophthalmic solution; Aerie) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Xelpros contains latanoprost, a prostaglandin F2α analogue that is believed to reduce IOP by increasing the outflow of aqueous humor.
The trial included 594 individuals with open-angle glaucoma or ocular hypertension. Participants were randomized to receive 3 administration cycles (Day 1, Week 16 and Week 32) of Bimatoprost SR or twice daily timolol eye drops.
The approval was based on results from 3 randomized trials which found that Rhopressa was associated with a reduction in intraocular pressure of up to 5mmHg.
“A simple static perimetry approach potentially yields high-quality results in children younger than 10 years,” the authors write.
Rhopressa (netarsudil ophthalmic solution) 0.02% is indicated for the reduction of elevated intraocular
pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
There were no significant associations between glaucoma and consumption of caffeinated and decaffeinated coffee, iced tea, and soft drinks.
Vyzulta works by metabolizing into two moieties, latanoprost acid, which primarily works within the uveoscleral pathway to increase aqueous humor outflow, and butanediol mononitrate, which releases NO to increase outflow through the trabecular meshwork and Schlemm’s canal.
The recall applies to Combigan 0.2%/0.5% lots in 2.5mL, 5mL, 10mL and 15mL sizes, and one lot of Lumigan 0.01%.
The evaluation of Roclatan has been ongoing in two distinct trials.
